biotech

research

Amgen Earnings Point to New 52-Week High

Amgen Corp. (NASDAQ: AMGN) reported fiscal second quarter 2015 earnings Thursday afternoon after equity markets had closed. The biotech firm posted adjusted earnings per share (EPS) of $2.57 on revenues ...
Read Full Story »
biotech

What to Expect from Amgen Earnings

Amgen Inc. (NASDAQ: AMGN) is scheduled to report its earnings after the markets close on Thursday. There are consensus estimates from Thomson Reuters that call for $2.43 in earnings per ...
Read Full Story »
biotech

Should Gilead Really Be Rated Underperform?

Most analysts seem to be behind the growth that Gilead Sciences Inc. (NASDAQ: GILD) has seen, namely in its Hepatitis C vaccines (HCV) Harvoni and Solvaldi. For the most part ...
Read Full Story »
E000249

Who Really Won in the PDL and Ariad Royalty Deal?

The solid performance of the healthcare sector over the past year has been enhanced by mergers and acquisitions, licensing, and other forms of deals in the sector. This most recent ...
Read Full Story »
coins

Dermira Files For Secondary Offering

Dermira, Inc. (NASDAQ: DERM) filed an S-1 form with the Securities and Exchange Commission (SEC) for a secondary offering. There were no terms given in this initial filing but the ...
Read Full Story »
gilead

Gilead Tops Estimates in 2Q

Gilead Sciences Inc. (NASDAQ: GILD) reported second-quarter financial results Tuesday after the markets closed. The biotech giant had $3.15 in earnings per share (EPS) on $8.2 billion in revenue compared ...
Read Full Story »
research

Was the Immunomedics Sell-Off Too Extreme?

Belgian pharmaceutical group UCB announced Tuesday morning that its phase 3 trial for lupus treatment epratuzumab failed to produce statistically significant results in both dosages tested in Systemic Lupus Erythematosus ...
Read Full Story »
biotech

Can Nymox Sustain This Massive Rally?

Nymox Pharmaceutical Corp. (NASDAQ: NYMX) was one of the best performers on Monday despite a down day in the market. And Nymox is absolutely dominating in 2015 in terms of its ...
Read Full Story »
biotech

Aimmune Prepares For IPO By Setting Expected Price Range

Aimmune Therapeutics, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering. The expected price range was set as $14 to $16 for ...
Read Full Story »
biotech

Short Sellers Back Off Major Biotechs

The short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

Pharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. ...
Read Full Story »
cemetery

Is This the End of Sunesis?

Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) probably wishes that this Friday never happened. The company was already a very speculative cancer drug biotech outfit, and now its status is moving down ...
Read Full Story »
biotech

Why Biogen Shares Are Tumbling After Earnings Report

Biogen Inc. (NASDAQ: BIIB) reported second-quarter 2015 results before markets opened Friday. The biotech firm posted adjusted diluted earnings per share (EPS) of $4.22 on revenues of $2.59 billion. In ...
Read Full Story »
Money, US, $100 bills

What to Look for in Biogen Earnings Report

Biogen Inc. (NASDAQ: BIIB) is scheduled to release its second-quarter financial results before the markets open on Friday. Thomson Reuters has consensus estimates of $4.10 in earnings per share (EPS) ...
Read Full Story »
knees

Can Cara Ultimately Get Its Drug Approved?

Cara Therapeutics Inc. (NASDAQ: CARA) may not be a household name, but the company is working toward an approval. The company saw its shares scream higher on Thursday after clearing ...
Read Full Story »